• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一步法 F 标记前列腺特异性膜抗原三氟硼酸盐探针用于癌症成像的研究。

One-Step F-Labeling and Preclinical Evaluation of Prostate-Specific Membrane Antigen Trifluoroborate Probes for Cancer Imaging.

机构信息

BC Cancer, Vancouver, British Columbia, Canada.

Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada; and.

出版信息

J Nucl Med. 2019 Aug;60(8):1160-1166. doi: 10.2967/jnumed.118.216598. Epub 2019 Feb 8.

DOI:10.2967/jnumed.118.216598
PMID:30737299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6681697/
Abstract

After the identification of the high-affinity glutamate-ureido scaffold, the design of several potent F- and Ga-labeled tracers has allowed spectacular progress in imaging recurrent prostate cancer by targeting the prostate-specific membrane antigen (PSMA). We evaluated a series of PSMA-targeting probes that are F-labeled in a single step for PET imaging of prostate cancer. We prepared 8 trifluoroborate constructs for prostate cancer imaging, to study the influence of the linker and the trifluoroborate prosthetic on pharmacokinetics and image quality. After 1-step labeling by F-F isotopic exchange, the radiotracers were injected in mice bearing LNCaP xenografts, with or without blocking controls, to assess specific uptake. PET/CT images and biodistribution data were acquired at 1 h after injection and compared with F-DCFPyL on the same mouse strain and tumor model. All tracers exhibited nanomolar affinities, were labeled in good radiochemical yields at high molar activities, and exhibited high tumor uptake in LNCaP xenografts with clearance from nontarget organs. Most derivatives with a naphthylalanine linker showed significant gastrointestinal excretion. A radiotracer incorporating this linker with a dual trifluoroborate-glutamate labeling moiety showed high tumor uptake, low background activity, and no liver or gastrointestinal track accumulation. PSMA-targeting probes with trifluoroborate prosthetic groups represent promising candidates for prostate cancer imaging because of facile labeling while affording high tumor uptake values and contrast ratios that are similar to those obtained with F-DCFPyL.

摘要

在鉴定出高亲和力谷氨酸脲支架后,设计了几种有效的 F 和 Ga 标记示踪剂,通过靶向前列腺特异性膜抗原 (PSMA),在复发性前列腺癌成像方面取得了显著进展。我们评估了一系列通过 F-F 同位素交换一步法进行 PET 成像的 PSMA 靶向探针,用于前列腺癌成像。我们制备了 8 个用于前列腺癌成像的三氟硼酸盐结构,以研究连接子和三氟硼酸盐假体对药代动力学和图像质量的影响。通过 F-F 同位素交换一步标记后,将放射性示踪剂注射到携带 LNCaP 异种移植物的小鼠中,有无阻断对照,以评估特异性摄取。在注射后 1 小时采集 PET/CT 图像和生物分布数据,并与同一小鼠品系和肿瘤模型上的 F-DCFPyL 进行比较。所有示踪剂均表现出纳摩尔亲和力,在高摩尔活性下以良好的放射化学产率标记,并在 LNCaP 异种移植物中表现出高肿瘤摄取,从非靶器官清除。带有萘基丙氨酸连接子的大多数衍生物显示出明显的胃肠道排泄。带有双三氟硼酸盐-谷氨酸标记部分的带有这种连接子的放射性示踪剂显示出高肿瘤摄取、低背景活性,并且没有肝脏或胃肠道积聚。由于易于标记,具有三氟硼酸盐假体基团的 PSMA 靶向探针是前列腺癌成像的有前途的候选物,因为它们具有高肿瘤摄取值和与 F-DCFPyL 相似的对比比。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/b29c7b5d6e36/1160fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/6090e944d1e6/1160fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/d8adbb710312/1160fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/f59c3d9406d5/1160fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/6b16b0509cb1/1160fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/969770476133/1160fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/b29c7b5d6e36/1160fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/6090e944d1e6/1160fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/d8adbb710312/1160fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/f59c3d9406d5/1160fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/6b16b0509cb1/1160fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/969770476133/1160fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2afd/6681697/b29c7b5d6e36/1160fig6.jpg

相似文献

1
One-Step F-Labeling and Preclinical Evaluation of Prostate-Specific Membrane Antigen Trifluoroborate Probes for Cancer Imaging.一步法 F 标记前列腺特异性膜抗原三氟硼酸盐探针用于癌症成像的研究。
J Nucl Med. 2019 Aug;60(8):1160-1166. doi: 10.2967/jnumed.118.216598. Epub 2019 Feb 8.
2
Synthesis and pre-clinical evaluation of a new class of high-affinity F-labeled PSMA ligands for detection of prostate cancer by PET imaging.一类用于正电子发射断层扫描(PET)成像检测前列腺癌的新型高亲和力F标记前列腺特异性膜抗原(PSMA)配体的合成及临床前评估。
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):647-661. doi: 10.1007/s00259-016-3556-5. Epub 2016 Nov 15.
3
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
4
Preclinical Evaluation and Pilot Clinical Study of AlF-PSMA-BCH for Prostate Cancer PET Imaging.用于前列腺癌 PET 成像的 AlF-PSMA-BCH 的临床前评估和初步临床研究。
J Nucl Med. 2019 Sep;60(9):1284-1292. doi: 10.2967/jnumed.118.221671. Epub 2019 Feb 22.
5
In Vitro and In Vivo Characterization of an F-AlF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts.F-AlF 标记的 PSMA 配体的体外和体内特性分析用于 PSMA 表达异种移植的成像。
J Nucl Med. 2019 Jul;60(7):1017-1022. doi: 10.2967/jnumed.118.218941. Epub 2019 Jan 17.
6
Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.靶向前列腺特异性膜抗原(PSMA)的 F-18 标记化合物:侧基对肿瘤摄取和清除特性的影响。
Mol Imaging Biol. 2017 Dec;19(6):923-932. doi: 10.1007/s11307-017-1102-x.
7
Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.用于前列腺癌正电子发射断层显像(PET)的新型靶向前列腺特异性膜抗原的18F标记探针的合成与生物学评价
J Nucl Med. 2016 Dec;57(12):1978-1984. doi: 10.2967/jnumed.116.175810. Epub 2016 Jul 14.
8
Effects of Linker Modification on Tumor-to-Kidney Contrast of Ga-Labeled PSMA-Targeted Imaging Probes.连接子修饰对 Ga 标记的 PSMA 靶向成像探针肿瘤与肾脏对比的影响。
Mol Pharm. 2018 Aug 6;15(8):3502-3511. doi: 10.1021/acs.molpharmaceut.8b00499. Epub 2018 Jul 3.
9
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.一种定制的、带有优化连接基团的DOTA偶联PSMA抑制剂用于前列腺癌成像和内放射治疗的临床前评估
J Nucl Med. 2015 Jun;56(6):914-20. doi: 10.2967/jnumed.114.147413. Epub 2015 Apr 16.
10
Preclinical Evaluation of F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging.新型前列腺特异性膜抗原配体F-PSMA-1007用于前列腺癌成像的临床前评估
J Nucl Med. 2017 Mar;58(3):425-431. doi: 10.2967/jnumed.116.181768. Epub 2016 Oct 27.

引用本文的文献

1
Tracing prostate cancer - the evolution of PET-CT applications.追踪前列腺癌——PET-CT应用的发展历程
Rep Pract Oncol Radiother. 2024 Dec 4;29(5):627-637. doi: 10.5603/rpor.102615. eCollection 2024.
2
A versatile fluorinated azamacrocyclic chelator enabling F PET or F MRI: a first step towards new multimodal and smart contrast agents.一种多功能氟化氮杂大环螯合剂,可用于氟正电子发射断层扫描(F PET)或氟磁共振成像(F MRI):迈向新型多模态智能造影剂的第一步。
Chem Sci. 2024 Jul 25;15(33):13550-13557. doi: 10.1039/d4sc02871f. eCollection 2024 Aug 22.
3
PSMA imaging as a non-invasive tool to monitor inducible gene expression in vivo.

本文引用的文献

1
Phase I Study of CTT1057, an F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer.CTT1057 的 I 期研究,一种 F 标记的成像剂,其磷酰胺核心靶向前列腺特异性膜抗原用于前列腺癌。
J Nucl Med. 2019 Jul;60(7):910-916. doi: 10.2967/jnumed.118.220715. Epub 2018 Nov 21.
2
Discovery of F-JK-PSMA-7, a PET Probe for the Detection of Small PSMA-Positive Lesions.发现 F-JK-PSMA-7,一种用于检测小 PSMA 阳性病变的 PET 探针。
J Nucl Med. 2019 Jun;60(6):817-823. doi: 10.2967/jnumed.118.218495. Epub 2018 Nov 2.
3
Ga-PSMA is a novel PET-CT tracer for imaging of hepatocellular carcinoma: A prospective pilot study.
前列腺特异性膜抗原(PSMA)成像作为一种监测体内诱导基因表达的非侵入性工具。
EJNMMI Res. 2024 Jan 4;14(1):3. doi: 10.1186/s13550-023-01063-5.
4
Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands.Lys-urea-Aad、Lys-urea-Cmc 和 Lys-urea-Cms 作为设计 PSMA 靶向放射性配体的潜在药效团,以减少肾脏和唾液腺的非靶位摄取。
Theranostics. 2023 Aug 15;13(13):4559-4573. doi: 10.7150/thno.87663. eCollection 2023.
5
Synthesis and Evaluation of Tc-Labeled PSMA-Targeted Tracers Based on the Lys-Urea-Aad Pharmacophore for Detecting Prostate Cancer with Single Photon Emission Computed Tomography.基于赖氨酸-尿素-氨甲酰基药效团的 Tc 标记 PSMA 靶向示踪剂的合成与评价用于单光子发射计算机断层扫描检测前列腺癌。
Molecules. 2023 Jun 29;28(13):5120. doi: 10.3390/molecules28135120.
6
The "Ins and Outs" of Prostate Specific Membrane Antigen (PSMA) as Specific Target in Prostate Cancer Therapy.前列腺特异性膜抗原(PSMA)作为前列腺癌治疗特异性靶点的“来龙去脉”。
Adv Exp Med Biol. 2023;1408:291-308. doi: 10.1007/978-3-031-26163-3_16.
7
Synthesis and Preclinical Evaluation of Three Novel Ga-Labeled Bispecific PSMA/FAP-Targeting Tracers for Prostate Cancer Imaging.三种新型 Ga 标记的双特异性 PSMA/FAP 靶向探针用于前列腺癌成像的合成与临床前评价。
Molecules. 2023 Jan 21;28(3):1088. doi: 10.3390/molecules28031088.
8
What a difference a methylene makes: replacing Glu with Asp or Aad in the Lys-urea-Glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake.亚甲基的差异:在 PSMA 靶向放射性配体的 Lys-urea-Glu 药效团中用 Asp 或 Aad 替代 Glu,以减少肾脏和唾液腺摄取。
Theranostics. 2022 Aug 21;12(14):6179-6188. doi: 10.7150/thno.76571. eCollection 2022.
9
Radiolabeled PSMA Inhibitors.放射性标记的前列腺特异性膜抗原(PSMA)抑制剂
Cancers (Basel). 2021 Dec 13;13(24):6255. doi: 10.3390/cancers13246255.
10
Preclinical Evaluation of a Fluorine-18 Labeled Probe for the Detection of the Expression of PSMA Level in Cancer.一种用于检测癌症中前列腺特异性膜抗原(PSMA)水平表达的氟-18标记探针的临床前评估
ACS Omega. 2021 Mar 17;6(12):8279-8287. doi: 10.1021/acsomega.0c06353. eCollection 2021 Mar 30.
镓-前列腺特异性膜抗原是一种用于肝细胞癌成像的新型正电子发射断层扫描-计算机断层扫描示踪剂:一项前瞻性试点研究。
J Nucl Med. 2019 Feb 1;60(2):185-191. doi: 10.2967/jnumed.118.214833. Epub 2018 Jul 12.
4
Effects of Linker Modification on Tumor-to-Kidney Contrast of Ga-Labeled PSMA-Targeted Imaging Probes.连接子修饰对 Ga 标记的 PSMA 靶向成像探针肿瘤与肾脏对比的影响。
Mol Pharm. 2018 Aug 6;15(8):3502-3511. doi: 10.1021/acs.molpharmaceut.8b00499. Epub 2018 Jul 3.
5
Melanoma Imaging Using F-Labeled α-Melanocyte-Stimulating Hormone Derivatives with Positron Emission Tomography.基于正电子发射断层扫描的 F 标记 α-促黑素细胞激素衍生物在黑素瘤成像中的应用。
Mol Pharm. 2018 Jun 4;15(6):2116-2122. doi: 10.1021/acs.molpharmaceut.7b01113. Epub 2018 May 10.
6
Preliminary evaluation of F-labeled LLP2A-trifluoroborate conjugates as VLA-4 (αβ integrin) specific radiotracers for PET imaging of melanoma.F 标记的 LLP2A-三氟硼酸盐缀合物作为 VLA-4(αβ 整合素)特异性放射性示踪剂用于黑色素瘤 PET 成像的初步评价。
Nucl Med Biol. 2018 Jun;61:11-20. doi: 10.1016/j.nucmedbio.2018.02.005. Epub 2018 Mar 12.
7
Production of curie quantities of Ga with a medical cyclotron via the Zn(p,n)Ga reaction.利用医用回旋加速器通过锌(质子,中子)镓反应生产居里量的镓。
Appl Radiat Isot. 2018 Mar;133:1-3. doi: 10.1016/j.apradiso.2017.12.010. Epub 2017 Dec 9.
8
Comparison of Ga-PSMA-11 and F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence.10 例前列腺癌复发患者的 Ga-PSMA-11 和 F-Fluciclovine PET/CT 比较病例系列研究
J Nucl Med. 2018 May;59(5):789-794. doi: 10.2967/jnumed.117.203257. Epub 2017 Dec 14.
9
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.F-18标记的PSMA-1007:前列腺癌患者肿瘤病灶的生物分布、辐射剂量测定及组织病理学验证
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688. doi: 10.1007/s00259-016-3573-4. Epub 2016 Nov 26.
10
Preclinical Evaluation of F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging.新型前列腺特异性膜抗原配体F-PSMA-1007用于前列腺癌成像的临床前评估
J Nucl Med. 2017 Mar;58(3):425-431. doi: 10.2967/jnumed.116.181768. Epub 2016 Oct 27.